Table 1.
Pharmacological Treatment Options for Functional Dyspepsia Based on Double-Blind Randomized Placebo-Controlled Trials
| Level of evidence | Comment |
|---|---|
| Helicobacter pylori eradication (level 1) | First line therapy in infected |
| Acid suppression (level 1) | |
| Proton pump inhibitors | First line therapy especially for epigastric pain |
| H2 receptor antagonists | |
| Prokinetic (level 1–2) | |
| Cisapride | Cisapride withdrawn |
| Acotiamide | Available in Japan |
| Itopride | Mixed data |
| Centrally acting drugs (level 1–2) | |
| Tricyclic low dose (level 1) | Epigastric pain improved |
| Mirtazapine (level 2) | Efficacy not established |
| Buspirone (level 2) | Postprandial distress syndrome improved |
| Miscellaneous therapy | |
| Iberogast (level 2) | Relaxes the gastric fundus |
| Montelukast | One small pediatric trial |
| Not efficacious | |
| Selective serotonin reuptake inhibitors | |
| Selective norepinephrine reuptake inhibitors | |
| Antacids | |
| Sucralfate | |
| Bismuth | |
| Mosapride | |